Once-weekly insulin jab for type 2 diabetes authorised by MHRA

A new once-weekly insulin treatment for adults with type 2 diabetes has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA). Onswik (insulin efsitora alfa) is a long-acting basal insulin that could cut the injections needed by patients currently on daily treatment from 365 a year to 52. According to Julian Beach, MHRA...Read moreThe post Once-weekly insulin jab for type 2 diabetes authorised by MHRA appeared first on Nursing in Practice.